Astellas partners with CUOG to advance uro-oncology research in Canada
MARKHAM, ON, April 17, 2013 /CNW/ - Genitourinary cancer research in Canada
will receive additional funding thanks to a new research collaboration between
the Canadian Urologic Oncology Group (CUOG) and Astellas Pharma Canada, Inc.
This year, Astellas has pledged $50,000 to further Canadian investigators'
peer-reviewed research into finding medicines and cures for urological
disorders, focusing specifically on prostate cancer.
The CUOG/Astellas Research Awards in prostate cancer will range between
$10,000 and $25,000 each, depending on the number of applicants received, and
are in addition to Astellas' multi-year commitment to the Canadian urology
community through the CUA Astellas Research Grant program.
"For over 20 years, the Canadian Urologic Oncology Group has promoted research
by students, residents and fellows through annual CUOG awards. Under the
supervision of CUOG members, students have conducted research that has led to
some extremely valuable findings and, in many cases, served as the foundation
for larger projects and research careers," says Dr. Fred Saad, Chair of the
National Cancer Institute of Canada G-U Group and the Canadian Urologic
Oncology Group. "We are very pleased to be able to increase the amount of
money available for CUOG awards due to additional funding provided by Astellas
Urology continues to be a priority therapeutic area for Astellas and the
company is proud to support the efforts of the Canadian urology community
through its ongoing contributions to investigator research and patient
"Innovations that result from discovery research can potentially have a great
impact on patients in the future," says Michael Tremblay, President, Astellas
Pharma Canada. "We are honoured to contribute to advancing uro-oncology
research, with the hope that one day it will produce a cure for genitourinary
Applications for the CUOG/Astellas Research Awards are due May 1, 2013 and the
recipients will be announced at the annual CUOG meeting on June 22.
For more information, please visit CUOG's website, www.cuog.org.
About the Canadian Urologic Oncology Group (CUOG)
The Canadian Urologic Oncology Group (CUOG) is a clinical research
investigator network of leading academic and community based urologists,
medical oncologists, and radiation oncologists, committed to furthering
genitourinary (GU) cancer research in Canada.
CUOG pursues clinical trials in concert with the pharmaceutical industry to
find medicines and cures to tackle urological disorders including, but not
-- Prostate cancer
-- Bladder cancer
-- Renal cancer
-- Testicular cancer
More information about CUOG can be found at www.cuog.org.
About Astellas Pharma Canada, Inc.
Astellas Pharma Canada, Inc., headquartered in Markham, ON, is a Canadian
affiliate of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical
company dedicated to improving the health of people around the world through
the provision of innovative and reliable pharmaceutical products.
The organization is committed to becoming a global category leader in focused
areas by combining outstanding R&D and marketing capabilities. In Canada,
Astellas has an intense commercial focus on five therapeutic areas - Urology,
Immunology, Infectious Disease, Dermatology and Oncology.
For more information about Astellas Pharma Canada, Inc., please visit the
corporate website: www.astellas.ca
Naomi Côté Corporate Communications Astellas Pharma Canada, Inc. (905)
SOURCE: Astellas Pharma Canada, Inc.
To view this news release in HTML formatting, please use the following URL:
CO: Astellas Pharma Canada, Inc.
NI: MTC HEA
-0- Apr/17/2013 12:30 GMT
Press spacebar to pause and continue. Press esc to stop.